Preclinical Evaluation of the Efficacy of α-Difluoromethylornithine and Sulindac Against SARS-CoV-2 Infection.

Viruses · 2025 · PMC12567796 · PMID 41157578

Europe PMC DOI

hedged sentences

0.0630

closest p · 1.3× alpha

0.0770

boldest claim

The sentences

marginally significantp = 0.063so close (0.05 < p ≤ 0.1)

The marginally significant decrease was observed in plasma putrescine levels in the DFMO-treated ( p = 0.063) and the DFMO/Sulindac-treated ( p = 0.053) aged male mouse groups ( Table S9 ). 3.2.3.

also in 26,082 other papers

did not reach statistical significancep = 0.077so close (0.05 < p ≤ 0.1)

The DFMO/Sulindac combination group had a mean survival of 9.25 dpi, although the difference in survival did not reach statistical significance ( Table S2B , p = 0.077).

also in 111,027 other papers

a decreasing trendno p-value reported

A decreasing trend in hazard ratio was noted in male mice; for example, male mice treated with Sulindac alone and DFMO/Sulindac had HRs of 0.27 and 0.16, respectively, indicating a significantly lower risk of death in these groups.

also in 47,180 other papers

showed a trendno p-value reported

The aged male mice showed a trend of increased survival with treatments compared to the untreated group, with survival rates of 0.5 in the DFMO-treated and Sulindac-treated groups and 0.75 in the DFMO/Sulindac group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.